Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Uni-Bio Science Group Ltd
0690Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Boshutai, a small molecule drug to treat diabetes. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agent for the treatment of Type 2 diabetes. In addition, the company is involved in the distribution of hydrogel wound dressing for post-skin injury and minimally invasive surgery wound healing. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong. Address: No. 20 Science Park East Avenue, Sha Tin, Hong Kong
Analytics
Precio Objetivo de WallStreet
–Relación P/E
3.3Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 0690
Análisis de dividendos 0690
Aumento del dividendo durante 5 años
–Crecimiento continuo
1 AñoRatio de pago medio en 5 años
–Tendencia del payout 0690
Valoración de la acción 0690
Finanzas 0690
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |